# A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

> **NCT05908409** · PHASE1,PHASE2 · RECRUITING · sponsor: **IDP Discovery Pharma S.L.** · enrollment: 37 (estimated)

## Conditions studied

- Multiple Myeloma (MM)
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Double Hit Lymphoma
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Chronic Lymphocytic Leukemia (CLL)
- Triple Hit Lymphoma

## Interventions

- **DRUG:** IDP-121

## Key facts

- **NCT ID:** NCT05908409
- **Lead sponsor:** IDP Discovery Pharma S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-05
- **Primary completion:** 2025-12-22
- **Final completion:** 2026-03-22
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05908409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05908409, "A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05908409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*